Τρίτη 26 Ιουνίου 2018

Cancers, Vol. 10, Pages 217: Nano-Pulse Stimulation for the Treatment of Pancreatic Cancer and the Changes in Immune Profile

Cancers, Vol. 10, Pages 217: Nano-Pulse Stimulation for the Treatment of Pancreatic Cancer and the Changes in Immune Profile

Cancers doi: 10.3390/cancers10070217

Authors: Siqi Guo Niculina I. Burcus James Hornef Yu Jing Chunqi Jiang Richard Heller Stephen J. Beebe

A Pancreatic cancer is a notorious malignant neoplasm with an extremely poor prognosis. Current standard of care is rarely effective against late-stage pancreatic cancer. In this study, we assessed nanopulse stimulation (NPS) as a local treatment for pancreatic cancer in a syngeneic mouse Pan02 pancreatic cancer model and characterized corresponding changes in the immune profile. A single NPS treatment either achieved complete tumor regression or prolonged overall survival in animals with partial tumor regression. While this is very encouraging, we also explored if this local ablation effect could also result in immune stimulation, as was observed when NPS led to the induction of immune-mediated protection from a second tumor challenge in orthotopic mouse breast and rat liver cancer models. In the Pan02 model, there were insufficient abscopal effects (1/10) and vaccine-like protective effects (1/15) suggesting that NPS-induced immune mechanisms in this model were limited. To evaluate this further, the immune landscape was analyzed. The numbers of both T regulatory cells (Tregs) and myeloid derived suppressor cells (MDSCs) in blood were significantly reduced, but memory (CD44+) T-cells were absent. Furthermore, the numbers of Tregs and MDSCs did not reduce in spleens compared to tumor-bearing mice. Very few T-cells, but large numbers of MDSCs were present in the NPS treated tumor microenvironment (TME). The number of dendritic cells in the TME was increased and multiple activation markers were upregulated following NPS treatment. Overall, NPS treatments used here are effective for pancreatic tumor ablation, but require further optimization for induction of immunity or the need to include effective combinational NPS therapeutic strategy for pancreatic cancer.



https://ift.tt/2yM6rS5

T cell receptor repertoire profiling predicts the prognosis of HBV‐associated hepatocellular carcinoma

Cancer Medicine, EarlyView.


https://ift.tt/2yLIBWv

Editorial Board

alertIcon.gif

Publication date: August 2018
Source:Critical Reviews in Oncology/Hematology, Volume 128





https://ift.tt/2tHKXjk

Differentially expressed LncRNAs as potential prognostic biomarkers for glioblastoma

S22107762.gif

Publication date: October 2018
Source:Cancer Genetics, Volumes 226–227
Author(s): Mei Shao, Wenyun Liu, Yu Wang
Glioblastoma (GBM) is the most common and aggressive brain tumor with the poor clinical outcome. LncRNAs (Long non-coding RNAs) play an important role in the occurrence and development of glioblastoma. We aimed to explore the role that lncRNAs play in regulating glioblastoma and the pathways they are enriched in. The expression data of a total of 516 GBM samples were downloaded from TCGA (The Cancer Genome Atlas). We identified the differentially expressed lncRNAs between cancer and normal tissues and performed annotation of differentially expressed lncRNAs to figure out the functions and pathways they were enriched in. Finally, cluster analysis was performed on the expression data of lncRNA and the samples were divided into four kinds, which were then used in the survival analysis. A total of 90 down-regulated lncRNAs and 224 up-regulated lncRNAs were screened out, which were mostly enriched in pathways of Alzhermer's disease and apoptosis. Their neighborhood genes were mostly enriched in genes sets of RTN1 and MAPK10.The characterization of differentially expressed lncRNAs was found out and the mostly enriched pathways were obtained to figure out the regulation mechanism of lncRNA. Our findings may provide evidence of the potential role of lncRNA in the diagnosis, prognosis and target therapy of GBM.



https://ift.tt/2yO5ysc

Leukocyte differentiation by histidine-rich glycoprotein/stanniocalcin-2 complex regulates murine glioma growth through modulation of anti-tumor immunity

The plasma-protein histidine-rich glycoprotein (HRG) is implicated in phenotypic switching of tumor-associated macrophages, regulating cytokine production and phagocytotic activity, thereby promoting vessel normalization and anti-tumor immune responses. To assess the therapeutic effect of HRG gene delivery on CNS tumors, we used adenovirus-encoded HRG to treat mouse intracranial GL261 glioma. Delivery of Ad5-HRG to the tumor site resulted in a significant reduction in glioma growth, associated with increased vessel perfusion and increased CD45+ leukocyte and CD8+ T cell accumulation in the tumor. Antibody-mediated neutralization of colony-stimulating factor-1 suppressed the effects of HRG on CD45+ and CD8+ infiltration. Using a novel protein interaction-decoding technology, TRICEPS-based ligand receptor capture (LRC), we identified Stanniocalcin-2 (STC2) as an interacting partner of HRG on the surface of inflammatory cells in vitro and co-localization of HRG and STC2 in gliomas. HRG reduced the suppressive effects of STC2 on monocyte CD14+ differentiation and STC2-regulated immune response pathways. In consequence, Ad5-HRG treated gliomas displayed decreased numbers of Interleukin-35+ Treg cells, providing a mechanistic rationale for the reduction in GL261 growth in response to Ad5-HRG delivery. We conclude that HRG suppresses glioma growth by modulating tumor inflammation through monocyte infiltration and differentiation. Moreover, HRG acts to balance the regulatory effects of its partner, STC2, on inflammation and innate and/or acquired immunity. HRG gene delivery therefore offers a potential therapeutic strategy to control anti-tumor immunity.



https://ift.tt/2tHzlN9

Point of Care 2.0: Gerinnungsdiagnostik mit ROTEM® sigma und TEG® 6s

Anästhesiol Intensivmed Notfallmed Schmerzther 2018; 53: 412-424
DOI: 10.1055/s-0043-107755

TEG® 6s und ROTEM® sigma sind die neueste Generation von 2 häufig perioperativ eingesetzten Point-of-Care-Methoden zur Gerinnungsdiagnostik. Sie basieren auf Systemen zur automatischen Probenvorbereitung und -analyse mit Einweg-Testkassetten – personal- und zeitintensives Pipettieren entfällt größtenteils. Dieser Beitrag beschreibt die Testprinzipien und diskutiert Vor- und Nachteile bei der Integration der Methoden in den klinischen Alltag.
[...]

Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Abstract  |  Full text



https://ift.tt/2tuYUlE

Akutes Nierenversagen ist vermeidbar

Anästhesiol Intensivmed Notfallmed Schmerzther 2018; 53: 406-407
DOI: 10.1055/a-0633-7284



Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Full text



https://ift.tt/2KnhP88

Pflegemangel in Intensivmedizin führt zu Versorgungsengpässen

Anästhesiol Intensivmed Notfallmed Schmerzther 2018; 53: 405-405
DOI: 10.1055/a-0597-4562



Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Full text



https://ift.tt/2N3nu56

Notfall-Traumatologie: Endexspiratorischer CO2-Wert ist prädiktiv für Überleben

Anästhesiol Intensivmed Notfallmed Schmerzther 2018; 53: 406-406
DOI: 10.1055/a-0633-7339



Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Full text



https://ift.tt/2Iv5o8w

Point-of-Care-Diagnostik in der Traumatologie – Methoden und Evidenz

Anästhesiol Intensivmed Notfallmed Schmerzther 2018; 53: 440-457
DOI: 10.1055/s-0043-107753

Jeder 4. Schwerverletzte weist bereits bei Krankenhausaufnahme eine traumainduzierte Koagulopathie (TIK) auf, die mit einer 4-fach erhöhten Mortalität einhergeht. Rasche und zielgenaue Behandlung kann die TIK-assoziierte Sterblichkeit senken. Point-of-Care-Tests ermöglichen im Vergleich mit herkömmlichen Labormethoden eine zeitnahe und umfassende Bestimmung des Gerinnungsstatus sowie eine zielgerichtete Therapie.
[...]

Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Abstract  |  Full text



https://ift.tt/2tuUGdK

Abfall des endexspiratorischen CO2-Partialdrucks kann auf Anaphylaxie hinweisen

Anästhesiol Intensivmed Notfallmed Schmerzther 2018; 53: 407-408
DOI: 10.1055/a-0633-7322



Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Full text



https://ift.tt/2Itz71P

Interskalenäre Plexusblockade vs. Supraskapularisblockade in der Schulterchirurgie

Anästhesiol Intensivmed Notfallmed Schmerzther 2018; 53: 408-408
DOI: 10.1055/a-0633-7210



Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Full text



https://ift.tt/2IyHyZO

Point-of-Care-Gerinnungsdiagnostik in der Neurochirurgie

Anästhesiol Intensivmed Notfallmed Schmerzther 2018; 53: 425-439
DOI: 10.1055/s-0043-107754

Gerinnungsstörungen können für neurochirurgische Patienten gravierende Auswirkungen auf den Krankheitsverlauf und das Outcome haben: Blutungskomplikationen können zu intrakraniellem Druckanstieg und Schädigung des Gehirns führen. Somit hat die Gerinnungsdiagnostik und ggf. -therapie hier einen hohen Stellenwert. Dieser Beitrag beleuchtet die Anwendung moderner Point-of-Care-Verfahren zur Gerinnungsdiagnostik bei neurochirurgischen Patienten.
[...]

Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Abstract  |  Full text



https://ift.tt/2tuUrzm

Intranasales Ketamin wirksam bei Kindern mit frischen Frakturen

Anästhesiol Intensivmed Notfallmed Schmerzther 2018; 53: 408-409
DOI: 10.1055/a-0633-7255



Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Full text



https://ift.tt/2IueLVS

Der sichere Gefäßzugang – britisch-irische Leitlinie 2016

Anästhesiol Intensivmed Notfallmed Schmerzther 2018; 53: 458-465
DOI: 10.1055/s-0043-104546

Die Etablierung von Gefäßzugängen ist bei der Krankenversorgung die häufigste invasive Prozedur. Sie kann bei unsachgemäßer Durchführung äußerst traumatisierend für die Patientinnen und Patienten sein. Die neue Leitlinie der britisch-irischen Gesellschaft für Anästhesiologie wurde 2016 erstellt, da trotz existierender Handlungsempfehlungen immer noch schwere Komplikationen mit negativem Einfluss auf Morbidität und Mortalität auftreten.
[...]

Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Abstract  |  Full text



https://ift.tt/2tuUlYw

Die Rolle der Ernährung beim herzchirurgischen Patienten – eine Übersicht

Anästhesiol Intensivmed Notfallmed Schmerzther 2018; 53: 466-479
DOI: 10.1055/s-0043-121440

Der präoperative Ernährungsstatus und die perioperative Ernährungsstrategie spielen eine wichtige Rolle für das Outcome herzchirurgischer Patienten – dennoch gibt es nur wenige Studien zu Ernährungskonzepten für diese Patientengruppe. In diesem Beitrag werden die Ursachen der Mangelernährung, der Einfluss der Ernährungstherapie auf den herzchirurgischen Patienten und Strategien zur Verbesserung der Ernährung beschrieben.
[...]

Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Abstract  |  Full text



https://ift.tt/2KpN3eM

MicroRNA‐383 acts as a tumor suppressor in colorectal cancer by modulating CREPT/RPRD1B expression

Molecular Carcinogenesis, Volume 0, Issue ja, -Not available-.


https://ift.tt/2yS3C1Y

Epithelial to Mesenchymal Transition is Involved in Ethanol Promoted Hepatocellular Carcinoma Cells Metastasis and Stemness

Molecular Carcinogenesis, Volume 0, Issue ja, -Not available-.


https://ift.tt/2N2YATk

From hepatofibrosis to hepatocarcinogenesis: higher cytochrome P450 2E1 activity is a potential risk factor

Molecular Carcinogenesis, Volume 0, Issue ja, -Not available-.


https://ift.tt/2tIvQGx

Metallothionein 1 family profiling identifies MT1X as a tumor suppressor involved in the progression and metastastatic capacity of hepatocellular carcinoma

Molecular Carcinogenesis, Volume 0, Issue ja, -Not available-.


https://ift.tt/2N1pOJW

AKR1B10 Activates Diacylglycerol (DAG) Second Messenger in Breast Cancer Cells

Molecular Carcinogenesis, Volume 0, Issue ja, -Not available-.


https://ift.tt/2tHziky

Adaptive radiotherapy for head and neck cancers: Fact or fallacy to improve therapeutic ratio?

Publication date: May 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 3
Author(s): Y.Q. Li, J.S.H. Tan, J.T.S. Wee, M.L.K. Chua
Modern standards of precision radiotherapy, primarily driven by the technological advances of intensity modulation and image guidance, have led to increased versatility in radiotherapy planning and delivery. The ability to shape doses around critical normal organs, while simultaneously "painting" boost doses to the tumor have translated to substantial therapeutic gains in head and neck cancer patients. Recently, dose adaptation (or adaptive radiotherapy) has been proposed as a novel concept to enhance the therapeutic ratio of head and neck radiotherapy, facilitated in part by the onset of molecular and functional imaging. These contemporary imaging techniques have enabled visualisation of the spatial molecular architecture of the tumor. Daily cone-beam imaging, besides improving treatment accuracy, offers another unique angle to explore radiomics – a novel high throughput feature extraction and selection workflow, for adapting radiotherapy based on real-time tumor changes. Here, we review the existing evidence of molecular and functional imaging in head and neck cancers, as well as the current application of adaptive radiotherapy in the treatment of this tumor type. We propose that adaptive radiotherapy can be further exploited through a systematic application of molecular and functional imaging, including radiomics, at the different phases of planning and treatment.



https://ift.tt/2yLJ0s3

Issue Contents

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4





https://ift.tt/2MYKoKO

La curiethérapie : la plus ancienne des techniques modernes d’irradiation

1-s2.0-S1278321818X00055-cov150h.gif

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4
Author(s): C. Chargari, P. Maingon, F. Mornex, C. Haie-Méder




https://ift.tt/2yHY5Lb

Renaud Mazeron: A great scientist and teacher who contributed to GEC ESTRO for a decade. Tribute to Dr. Renaud Mazeron (1977–2016)

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4
Author(s): R. Nout, C. Kirisits, K. Tanderup, R. Pötter, C. Haie-Méder, B. Pieters, J. Lindegaard




https://ift.tt/2txSKko

Editorial Board

Publication date: April 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 2





https://ift.tt/2yKb7HX

Pourquoi la curiethérapie reste-t-elle indispensable en 2017 ?

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4
Author(s): C. Haie-Méder, P. Maroun, I. Fumagalli, I. Lazarescu, I. Dumas, F. Martinetti, C. Chargari
La curiethérapie a bénéficié ces dernières années de développements liés en particulier aux progrès de l'imagerie. L'utilisation plus systématique des images scanographiques, ultrasonographiques ou de l'imagerie par résonance magnétique (IRM) pendant la curiethérapie a permis de mieux définir les volumes d'intérêt, qu'il s'agisse des volumes tumoraux ou des organes à risque ainsi que leur rapport avec les applicateurs. De nouveaux concepts intégrant la régression tumorale en cours de traitement ont fait l'objet de définitions, et ont été validées cliniquement. De nouveaux applicateurs adaptés aux tumeurs ont été créés et sont disponibles sur le marché. Des processus d'optimisation de doses ont été développés, intégrant des possibilités d'hypofractionnement, et ont permis une amélioration des contrôles tumoraux. Toutes ces opportunités ont conduit à revisiter les indications de la curiethérapie dont les avantages balistiques restent incontestables, notamment en comparaison à la radiothérapie externe.These recent years, brachytherapy has benefited from imaging modalities advances. A more systematic use of tomodensitometric, ultrasonographic and MRI images during brachytherapy procedures has allowed an improvement in target and organs at risk assessment as well as their relationship with the applicators. New concepts integrating tumor regression during treatment have been defined and have been clinically validated. New applicators have been developed and are commercially available. Optimization processes have been developed, integrating hypofractionation modalities leading to tumor control improvement. All these opportunities led to further development of brachytherapy, with indisputable ballistic advantages, especially compared to external irradiation.



https://ift.tt/2tw15Fq

Radiobiology of brachytherapy: The historical view based on linear quadratic model and perspectives for optimization

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4
Author(s): C. Chargari, E. Van Limbergen, U. Mahantshetty, É. Deutsch, C. Haie-Méder
Most preclinical studies examining the radiobiology of brachytherapy have focused on dose rate effects. Scarcer data are available on other major parameters of therapeutic index, such as cell cycle distribution, repopulation or reoxygenation. The linear quadratic model describes the effect of radiotherapy in terms of normal tissue or tumour response. It allows some comparisons between various irradiation schemes. This model should be applied cautiously for brachytherapy, because it relies on cell death analysis only, and therefore partially reflects the biological effects of an irradiation. Moreover, the linear quadratic model validity has not been demonstrated for very high doses per fraction. A more thorough analysis of mechanisms involved in radiation response is required to better understand the true effect of brachytherapy on normal tissue. The modulation of immune response is one promising strategy to be tested with brachytherapy. A translational approach applied to brachytherapy should lead to design trials testing pharmacological agents modulating radiation response, in order to improve not only local control, but also decrease the risk of distant failure. Here we review the radiobiology of brachytherapy, from the historical view based on linear quadratic model to recent perspectives for biological optimization.



https://ift.tt/2yNPW7Y

Editorial Board

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4





https://ift.tt/2tt4tkr

Nouveaux algorithmes de calcul en curiethérapie pour les traitements par iridium 192

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4
Author(s): C. Robert, I. Dumas, F. Martinetti, C. Chargari, C. Haie-Meder, D. Lefkopoulos
Depuis 1995, les protocoles dosimétriques de curiethérapie suivent la méthodologie recommandée par le Task Group TG-43. Cette méthodologie, qui a l'avantage d'être très rapide, repose sur plusieurs approximations qui ne sont pas toujours valides en conditions cliniques. Les algorithmes de calcul de dose basés sur des modèles (model-based dose calculation algorithms, [MBDCA]) sont apparus récemment dans les stations de planification de traitement et sont considérés comme une évolution majeure en permettant notamment une prise en compte des dimensions finies du patient, des hétérogénéités tissulaires ou de la présence de matériaux de numéros atomiques élevés dans les applicateurs. En 2012, un rapport du groupe de travail 186 de l'American Association of Physicists in Medicine (AAPM) a fait un bilan de ces modèles et émis des recommandations pour leur mise en œuvre clinique. La présente revue s'intéresse à l'utilisation des algorithmes de calcul de dose basés sur des modèles dans le contexte des traitements par iridium 192. Après une description rapide de ceux-ci et de leur implémentation clinique, un bilan des questions principales soulevées par ces nouvelles méthodes est réalisé. Une réflexion sur le choix du milieu de spécification de la dose et sur la méthodologie d'assignation des caractéristiques des matériaux est notamment menée. Dans une dernière partie, des exemples concrets récents issus de la littérature illustrent les capacités de ces nouveaux algorithmes.Since 1995, the brachytherapy dosimetry protocols follow the methodology recommended by the Task Group 43. This methodology, which has the advantage of being fast, is based on several approximations that are not always valid in clinical conditions. Model-based dose calculation algorithms have recently emerged in treatment planning stations and are considered as a major evolution by allowing for consideration of the patient's finite dimensions, tissue heterogeneities and the presence of high atomic number materials in applicators. In 2012, a report from the American Association of Physicists in Medicine Radiation Therapy Task Group 186 reviews these models and makes recommendations for their clinical implementation. This review focuses on the use of model-based dose calculation algorithms in the context of iridium 192 treatments. After a description of these algorithms and their clinical implementation, a summary of the main questions raised by these new methods is performed. Considerations regarding the choice of the medium used for the dose specification and the recommended methodology for assigning materials characteristics are especially described. In the last part, recent concrete examples from the literature illustrate the capabilities of these new algorithms on clinical cases.



https://ift.tt/2yKMBq7

Metastatic mediastinal mature teratoma with malignant transformation in a young man with an adenocarcinoma in a Klinefelter's syndrome: Case report and review of the literature

Publication date: May 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 3
Author(s): C. Le Fèvre, C. Vigneron, H. Schuster, A. Walter, L. Marcellin, G. Massard, P. Lutz, G. Noël
Malignant transformation of mediastinal mature teratoma is extremely rare and worsens the prognosis of the disease. Transformation can appear synchronously to or several years after the initial diagnosis. Clinical and radiological signs can orientate the clinician but the definitive diagnosis is obtained thanks to histology. An 11 year-old boy presented with a mediastinal mature teratoma and bone and pulmonary metastases. He received six cycles of chemotherapy combining etoposide, ifosfamide, cisplatin, followed by resection of a 16×14×9cm mediastinal mass. Karyotype analysis revealed the presence of an additional sex chromosome X (47 XXY) pathognomonic of Klinefelter's syndrome. Ten years later, sciatalgia revealed malignant transformation of a pre-existing sacral bone metastasis into gastrointestinal adenocarcinoma. The patient received four cycles of chemotherapy combining oxaliplatin, 5-fluorouracil and cetuximab. This treatment was followed by a complete resection of the sacral metastasis and completed with adjuvant irradiation of 54Gy in 30 daily fractions. Twelve months after the diagnosis of relapse, the patient remained alive without disease. To our knowledge, this is the first case of adenocarcinoma developed in bone metastases of a mediastinal mature teratoma in a boy with a Klinefelter's syndrome. We propose a review of the literature and an analysis of 20 others published cases of mediastinal teratoma with malignant transformation into adenocarcinoma.



https://ift.tt/2tvNJsI

Place of modern imaging in brachytherapy planning

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4
Author(s): T.P. Hellebust
Imaging has probably been the most important driving force for the development of brachytherapy treatments the last 20 years. Due to implementation of three-dimensional imaging, brachytherapy is nowadays a highly accurate and reliable treatment option for many cancer patients. To be able to optimize the dose distribution in brachytherapy the anatomy and the applicator(s) or sources should be correctly localised in the images. For computed tomography (CT) the later criteria is easily fulfilled for most brachytherapy sites. However, for many sites, like cervix and prostate, CT is not optimal for delineation since soft tissue is not adequately visualized and the tumor is not well discriminated. For cervical cancer treatment planning based on magnetic resonance imaging (MRI) is recommended. Some centres also use MRI for postimplant dosimetry of permanent prostate seed implant and high dose rate prostate brachytherapy. Moreover, in so called focal brachytherapy where only a part of the prostate is treated, multiparametric MRI is an excellent tool that can assist in defining the target volume. Applicator or source localization is challenging using MRI, but tolls exist to assist this process. Also, geometrical distortions should be corrected or accounted for. Transrectal ultrasound is considered to be the gold standard for high dose rate prostate brachytherapy and transrectal ultrasound -based brachytherapy procedure offers a method for interactive treatment planning. Reconstruction of the needles is sometimes challenging, especially to identify the needle tip. The accuracy of the reconstruction could be improved by measuring the residuals needle length and by using a bi-planar transducer. The last decade several groups worldwide have explored the use of transrectal and transabdominal ultrasound for cervical cancer brachytherapy. Since ultrasonography is widely available, offers fast image acquisition and is a rather inexpensive modality such development is interesting. However, more work is needed to establish this as an adequate alternative for all phases of the treatment planning process. Studies using positron emission tomography imaging in combination with brachytherapy treatment planning are limited. However, development of new tracers may offer new treatment approaches for brachytherapy in the future. Combination of several image modalities will be the optimal solution in many situations, either during the same session or for different fractions. When several image modalities are combined so called image registration procedures are used and it is important to understand the principles and limitations of such procedures.



https://ift.tt/2yNPMNU

Implementation of failure mode and effective analysis for high dose rate brachytherapy at Tata Memorial Hospital, Mumbai, India

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4
Author(s): J. Swamidas, N. Khanna, U. Mahantshetty, V. Somesan, D.D. Deshpande, S.K. Shrivastava
PurposeTo report our experience of failure mode and effective analysis for high dose rate brachytherapy of gynaecological cancer carried out in our hospital.Materials and methodsFailure mode and effective analysis process described in AAPM TG 100 was followed: a multidisciplinary team consisting of two physicians, physicists, dosimetrists, a medical resident, a nurse, and a secretary was formed. A weekly meeting was held for four months. A process tree was created based on the overview of the entire process, with the main branches as follows: procedure in the operating room, patient imaging, contouring, treatment planning, machine quality assurance and treatment delivery. Each team member assigned the risk probability numbers based on the predefined scoring system. For a particular failure mode, if the risk probability number assigned by one member differed from the other, the highest risk probability number was taken into consideration.ResultsThe process tree consisted of 185 nodes, with risk probability numbers ranging from 1–220, with 77 possible failure modes. Four nodes were found with risk probability numbers greater than 200, which were considered for immediate process improvements. Twenty-four nodes were found to be with risk probability numbers ranging from 100 to 200. All 24 processes were considered for process improvement, out of which 12 were found effective and feasible, which includes failure nodes with high severity score at least 8. The processes with high-risk probability numbers (greater than 200) were reduced after the introduction of process improvements. For the other processes, standard procedures were modified. The common causes of failure, were found to be due to lack of attention, human error and work pressure.ConclusionsFailure mode and effective analysis is a useful tool that uses a systematic approach for quality management of a specific process.



https://ift.tt/2MYKkL4

Multicatheter interstitial brachytherapy for breast cancer

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4
Author(s): S. Sumodhee, V. Strnad, J.-M. Hannoun-Lévi
Brachytherapy remains the best irradiation technique to deliver a high dose in a small volume. Breast brachytherapy is part of the arsenal of therapy in the management of breast cancer. In this article, we present the technical data related to multicatheter interstitial brachytherapy to the breast proceeding, from the implantation of the vectors to the treatment itself. The indications for brachytherapy in breast cancer are boost after whole breast irradiation, accelerated partial breast irradiation or selected patients with second ipsilateral breast tumor event. The results in terms of efficacy and toxicity are presented for each indication. Multicatheter interstitial breast brachytherapy remains a major technique for breast cancer treatment.



https://ift.tt/2yLvIf2

3D brachytherapy for cervical cancer: New optimization ways

1-s2.0-S1278321818X00055-cov150h.gif

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4
Author(s): I. Fumagalli, C. Haie-Méder, C. Chargari
Brachytherapy has known major improvements in recent decades. It represents an essential component of local treatment of cervix cancers. One major breakthrough was the advent of 3D imaging for image-guided brachytherapy. Doses could be prescribed to volumes. This allows better delineation and coverage of target volumes, as well as organs at risk (bladder, rectum, sigmoid) protection. Local recurrences have been consequently reduced and survival has been improved. In addition, improvement and development of new applicators have facilitated the delivery of interstitial treatments. Afterloading applicators, associated with 3D imaging, allow dosimetry optimization in order to improve the coverage of the target volumes (dose in 90% of the high risk clinical target volume) and to limit dose to the organs at risk. In the future, more personalized treatments will be achieved through more advanced applicators and/or by improving the accuracy of imaging at the time of brachytherapy.



https://ift.tt/2N3RWvJ

Curiethérapie de la prostate : évolutions des indications et des techniques

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4
Author(s): P. Blanchard, P. Graff-Cailleaud, A. Bossi
La curiethérapie de prostate est depuis longtemps un des standards de traitements des cancers de la prostate à bas risque, avec des taux de contrôle biochimique très favorables et une toxicité tardive très compétitive sur les plans urinaire et sexuel sur le long terme par rapport aux alternatives thérapeutiques, que ce soit la radiothérapie externe ou la prostatectomie totale. L'objectif de cet article est de passer en revue les évolutions récentes de la technique et des indications, qui laissent présager un avenir intéressant pour la curiethérapie. Nous évoquons successivement l'extension des indications de la curiethérapie par implants permanents aux cancers de stade intermédiaire favorable, le développement de nouveaux isotopes, le palladium 103 et le césium 131, et l'utilisation de la curiethérapie comme méthode de complément d'irradiation dans les cancers de pronostics intermédiaire et défavorable, approche qui deviendra prochainement peut-être le nouveau standard de traitement. Nous abordons également la place de la curiethérapie de haut débit de dose, exclusive et de complément, celle de l'IRM dans la définition des indications et la planification thérapeutique, ainsi que les approches focales de curiethérapie.Prostate brachytherapy has been for a long time one of the standard treatments for low risk prostate cancer, with high rates of biochemical control and low levels of urinary and sexual late toxicity compared to other available techniques, namely external beam radiotherapy and radical prostatectomy. The aim of this article is to review the recent innovations of prostate brachytherapy, which suggest a bright future for the technique. We will discuss the extension of indications of permanent implant brachytherapy to favorable intermediate-risk patients, the use of novel isotopes such as Palladium 103 and Cesium 131, and the benefit of brachytherapy as a boost following external beam radiotherapy for intermediate and high-risk patients. We will also discuss the rise of high dose rate brachytherapy, as a boost or monotherapy, the increasing use of MRI for patient selection and treatment planning, as well as the development of brachytherapy as a means of focal therapy.



https://ift.tt/2tImN8e

Curiethérapie des cancers de la tête et du cou : synthèse des recommandations européennes et principales indications

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4
Author(s): D. Peiffert, B. Coche-Dequéant, M. Lapeyre, S. Renard
Les principales indications de curiethérapie des cancers de la tête et du cou localisées sont les tumeurs des lèvres et la pyramide nasale, de la cavité buccale et de l'oropharynx. Les tumeurs du cavum sont aujourd'hui plus accessibles à la radiothérapie conformationnelle avec modulation d'intensité. La curiethérapie peut être réalisée seule ou après une radiothérapie externe ou une chirurgie. Elle fait partie des traitements de recours pour les secondes localisations en territoire irradié et les situations périopératoires à risque. La curiethérapie de débit pulsé permet de reproduire les connaissances acquises de bas débit de dose et l'optimisation de la distribution de la dose. Les résultats de séries de patients traités avec le haut débit font leur apparition dans plusieurs localisations. Cet article fait état des données issues des recommandations du Groupe européen de curiethérapie–European Society for Radiotherapy and Oncology (Gec-ESTRO) publiées en 2017, tenant compte des connaissances issues des séries en bas débit de dose, et actualisées pour les techniques de débit pulsé et de haut débit de dose.The main indications of the brachytherapy of head and neck cancers are the limited tumours of the lip, the nose, the oral cavity and the oropharynx. Nasopharynx tumours are nowadays treated by intensity-modulated radiotherapy. This technique can be exclusive, associated with external radiotherapy or postoperative. It can also be a salvage treatment for the second primaries in previously irradiated areas. If the low dose rate brachytherapy rules remain the reference, the pulse dose rate technique allows the prescription of the dose rate and the optimisation of the dose distribution. Results of high dose rate brachytherapy are now published. This paper reports the recommendations of the Gec-ESTRO, published in 2017, and takes into account the data of the historical low dose rate series, and is upgraded with the pulsed-dose rate and high dose rate series.



https://ift.tt/2MWB4at

Trimodalities for bladder cancer in elderly: Transurethral resection, hypofractionated radiotherapy and gemcitabine

Publication date: May 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 3
Author(s): H.A.H. Mohamed, M.A. Salem, M.S. Elnaggar, A. Gabr, A.M. Abdelrheem
PurposeA prospective phase II study carried out to evaluate hypofractionated radiotherapy with concurrent gemcitabine for bladder preservation in the elderly patient with bladder cancer.Patients and methodsThirty-one patients were enrolled, age ≥65years, diagnosed with transitional cell carcinoma of the urinary bladder, after a maximum safe transurethral resection of a bladder tumour. They received 52.5Gy in 20 fractions using 3D conformal radiotherapy with concurrent 100mg/m2 gemcitabine weekly as a radiosensitizer.ResultsAll patients completed their radiation therapy course, while seven patients received their chemotherapy irregularly due to grade 3 toxicities. Twenty-five patients (80.6%) achieved a complete response. At 2-years, overall survival was 94.4% and disease-free survival was 72.6%. T3 and residual after transurethral resection are factors that adversely affect disease-free survival.ConclusionHypofractionated radiotherapy and gemcitabine as a radiosensitizer in elderly as organ preservation for transitional cell carcinoma bladder cancer have acceptable toxicity profile with good response rate and disease-free survival, keeping salvage cystectomy for persistence or recurrence of invasive cancer.



https://ift.tt/2yLFeip

Endoluminal brachytherapy: Bronchus and oesophagus

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4
Author(s): C. Hennequin, S. Guillerm, S. Wong, L. Quéro
Endobronchial brachytherapy could be proposed in case of endoluminal tumours either as a palliative or a curative treatment. As a curative treatment, endobronchial brachytherapy could obtain a high local control rate in case of limited disease. In palliative setting, endobronchial brachytherapy improved thoracic symptoms in more than 80% of cases, but it is less efficient than external beam radiation therapy for palliation. It could be also proposed to maintain the airway open after laser therapy. Oesophageal brachytherapy is a valuable option as a palliative treatment, underused at this time. It causes less side effects and a better quality of life compared to self-expanded metallic stents. For a curative aim, there is today no demonstration that a combination of external beam radiotherapy and oesophageal brachytherapy give better results than external beam radiotherapy alone in locally advanced tumours. For superficial diseases, the combination of external beam radiotherapy and oesophageal brachytherapy seems, on the contrary, promising.



https://ift.tt/2tw0zY0

Salvage brachytherapy as a modern reirradiation technique for local cancer failure: The Phoenix is reborn from its ashes

Publication date: June 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 4
Author(s): M. Quivrin, K. Peignaux-Casasnovas, É. Martin, M. Rouffiac, D. Thibouw, C. Chevalier, N. Vulquin, L. Aubignac, G. Truc, G. Créhange
The treatment of local recurrence of a previously irradiated cancer or a second cancer arising in-field remains challenging. Ultimately, the objective of salvage therapy is to control disease while ensuring minimal collateral damage, thereby optimizing both cancer and toxicity outcomes. Reirradiation has historically been associated with unacceptable toxicity and a limited benefit. Brachytherapy offers the best dose distribution and a high radiation dose to the target volume while better protecting surrounding previously irradiated healthy tissues. The management of local cancer recurrence in irradiated areas should be planned through multidisciplinary discussions and patients should be selected carefully. This overview of the literature describes brachytherapy as a reirradiation treatment in local recurrences of previously irradiated prostate, breast, head and neck and rectal cancers, or second primary cancers occurring in-field. For these cancers, the prognosis and therapeutic challenges are quite different and depend on the type of primary cancer. However, current data confirm that brachytherapy reirradiation is feasible and has acceptable toxicity.



https://ift.tt/2yNStz2

Méningiomes de la base du crâne : efficacité et tolérance clinique, efficacité radiologique et cinétique tumorale après radiothérapie

Publication date: May 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 3
Author(s): Y. Brahimi, D. Antoni, R. Srour, F. Proust, H. Cebula, A. Labani, G. Noël
Les méningiomes de la base du crâne entraînent des troubles fonctionnels qui peuvent significativement altérer la qualité de vie. La prise en charge optimale de ces lésions dont l'objectif est une préservation neurologique et le contrôle tumoral local n'est actuellement pas encore clairement établie. Il est largement reconnu aujourd'hui que l'objectif d'une exérèse tumorale radicale doit être abandonné et ce malgré les avancées dans le domaine de la microchirurgie des lésions de la base du crâne. Bien que moins morbide, l'exérèse tumorale partielle serait associée à un risque majoré de récidive tumorale locale. Bien que toujours discutée, la radiothérapie, aussi bien en traitement adjuvant qu'exclusif a largement fait les preuves d'excellents résultats en termes d'amélioration clinique et de contrôle local. Cependant, les taux d'amélioration clinique retrouvés contrastent avec de faibles taux d'amélioration radiologique. La notion d'une dissociation clinique et radiologique de l'irradiation des méningiomes de la base du crâne est apparue. Toutefois, dans la majorité de ces études, l'analyse de la réponse radiologique pouvait faire l'objet de critiques légitimes. Ce travail avait pour objectif de passer en revue le contrôle local, l'efficacité et la tolérance clinique et la réponse radiologique des différentes alternatives radiothérapeutiques des méningiomes de la base du crâne et de démontrer l'intérêt des analyses volumétriques quantitatives dans le suivi des méningiomes après radiothérapie.Skull base meningioma leads to functional disturbances, which can significantly alter the quality of life. The optimal management of these lesions, whose goals are neurological preservation and tumour local control, is not yet clearly established. It is widely recognized that the goal of a radical excision should be abandoned despite the advances in the field of microsurgery of skull base lesions. Although less morbid, partial tumour excision would be associated with increased risk of local tumour recurrence. Although discussed both exclusive and adjuvant have proven to be highly successful in terms of clinical improvement and local control. Various radiation techniques have demonstrated their efficacy in the management of this pathology. However, high rates of clinical improvement are in contrast with low rates of radiological improvement. The notion of clinical and radiological dissociation appeared. However, in most of these studies, the analysis of the radiological response could be subject of legitimate criticism. This work proposes to review the local control, the efficacy and the clinical tolerance and the radiological response of the various radiation techniques for the meningioma of the base of the skull and to demonstrate the interest of quantitative volumetric analyses in the follow-up of meningioma after radiotherapy.



https://ift.tt/2txrO4u

Suicidal jumper’s fracture – sacral fractures and spinopelvic instability: a case series

Sacral fractures with spinopelvic dissociation are rare, and hard to diagnose and treat. Fractures with a H- or U-shaped line are severely unstable, due to a dissociation of the spine and of the upper body of ...

https://ift.tt/2KrAe3X

Intracranial meningeal melanocytoma diagnosed using an interdisciplinary approach: a case report and review of the literature

Meningeal melanocytoma is a rare pigmented tumor arising from leptomeningeal melanocytes. Patients with this tumor might initially consult a dentist because a mass lesion in Meckel's cave could manifest as den...

https://ift.tt/2tuR0Zw

Intrathoracic pressure regulation therapy applied to ventilated patients for treatment of compromised cerebral perfusion from brain injury

Reducing intrathoracic pressure in the setting of compromised cerebral perfusion due to acute brain injury has been associated with reduced intracranial pressure and enhanced cerebral perfusion pressure and bl...

https://ift.tt/2KoxvYQ

Migratory polyarthritis as a paraneoplastic syndrome in a patient with diffuse large B cell lymphoma: a case report

Diffuse large B cell lymphoma is the commonest histological subtype of non-Hodgkin lymphoma and typically presents as a rapidly enlarging lymph node mass and B symptoms. It is unusual for diffuse large B cell ...

https://ift.tt/2K9mpLf

Relationship of demoralization with anxiety, depression and quality of life: A Southern European study of Italian and Portuguese cancer patients

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KaEgBE

The risk factors for depression in Lithuanian breast cancer patients

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2IrbSW5

Self‐expression and identity after total laryngectomy: Implications for support

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KnOU7m

Depressive symptoms in relation to overall survival in people with head and neck cancer: a longitudinal cohort study

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2MooTlK

Differences in health care professionals’ and cancer patients’ views on sexual health issues

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KnOQVa

Does Sharing Good News Buffer Fear of Bad News? A Daily Diary Study of Fear of Cancer Recurrence in Couples Approaching the First Mammogram Post‐Diagnosis

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Mo9oKm

School performance of childhood cancer survivors in Korea: a multi‐institutional study on behalf of the Korean Society of Pediatric Hematology and Oncology

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KaDTXM

Work‐specific cognitive symptoms and the role of work characteristics, fatigue and depressive symptoms in cancer patients during 18 months post return to work

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2MslfqG

Psychosocial mediators of dietary change among Hispanic/Latina breast cancer survivors in a culturally‐tailored dietary intervention

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KnncHL

An investigation of the relationship between social support and coping with stress in women with breast cancer

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Msl4f0

Self‐Reported Chemotherapy‐Related Cognitive Impairment Compared with Cognitive Complaints following Menopause

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KdW0vK

Naturalistically Observing Non‐Cancer Conversations among Couples Coping with Breast Cancer

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2ItxdhF

Examining the role of social support and spirituality on the general health perceptions of Hispanic cancer survivors

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KqhPY8

Culturally and linguistically diverse oncology patients’ perspectives of consultation audio recordings and question prompt lists

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2MlxxkE

Recruitment problems in psychosocial oncology research

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Kcbgcr

Are psychological interventions effective on anxiety in cancer patients? A systematic review and meta‐analyses

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2IyrZ4k

The Lived Experience of Head and Neck Cancer Patients Receiving Curative Radiotherapy: A Systematic Review and Meta‐Ethnography.

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KdjJML

Health‐related quality of life and psychological distress among cancer survivors in a middle‐income country

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2MqEYY9

Preferences for models of peer support in the digital era: A cross‐sectional survey of people with cancer

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KnOGgw

One way or another: The opportunities and pitfalls of self‐referral and consecutive sampling as recruitment strategies for psycho‐oncology intervention trials.

Psycho-Oncology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2MpPPBm

Parotid gland fat related Magnetic Resonance image biomarkers improve prediction of late radiation-induced xerostomia

This study investigated whether Magnetic Resonance image biomarkers (MR-IBMs) were associated with xerostomia 12 months after radiotherapy (Xer12m) and to test the hypothesis that the ratio of fat-to-functional parotid tissue is related to Xer12m. Additionally, improvement of the reference Xer12m model based on parotid gland dose and baseline xerostomia, with MR-IBMs was explored.

https://ift.tt/2MYSnYh

The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma

Abstract
Background
Virtually all low-grade gliomas (LGGs) will progress to high-grade gliomas (HGGs), including glioblastoma, the most common malignant primary brain tumor in adults. A key regulator of immunosuppression, fibrinogen-like protein 2 (FGL2), may play an important role in the malignant transformation of LGG to HGG. We sought to determine the mechanism of FGL2 on tumor progression and to show that inhibiting FGL2 expression had a therapeutic effect.
Methods
We analyzed human gliomas that had progressed from low- to high-grade for FGL2 expression. We modeled FGL2 overexpression in an immunocompetent genetically engineered mouse model to determine its effect on tumor progression. Tumors and their associated microenvironments were analyzed for their immune cell infiltration. Mice were treated with an FGL2 antibody to determine a therapeutic effect. Statistical tests were two-sided.
Results
We identified increased expression of FGL2 in surgically resected tumors that progressed from low to high grade (n = 10). The Cancer Genome Atlas data showed that LGG cases with overexpression of FGL2 (n = 195) had statistically significantly shorter survival (median = 62.9 months) compared with cases with low expression (n = 325, median = 94.4 months, P < .001). In a murine glioma model, HGGs induced with FGL2 exhibited a mesenchymal phenotype and increased CD4+ forkhead box P3 (FoxP3)+ Treg cells, implicating immunosuppression as a mechanism for tumor progression. Macrophages in these tumors were skewed toward the immunosuppressive M2 phenotype. Depletion of Treg cells with anti-FGL2 statistically significantly prolonged survival in mice compared with controls (n = 11 per group, median survival = 90 days vs 62 days, P = .004), shifted the phenotype from mesenchymal HGG to proneural LGG, and decreased M2 macrophage skewing.
Conclusions
FGL2 facilitates glioma progression from low to high grade. Suppressing FGL2 expression holds therapeutic promise for halting malignant transformation in glioma.

https://ift.tt/2tuHqpu

Relatively favorable prognosis for MLL‐rearranged childhood acute leukemia with reciprocal translocations

Pediatric Blood &Cancer, EarlyView.


https://ift.tt/2KmyqMJ

Outcome of landmark‐guided percutaneously inserted tunneled central venous catheters in infants and children under 3 years with cancer

Pediatric Blood &Cancer, EarlyView.


https://ift.tt/2IuhAGC

Evaluation of mobile phone applications to support medication adherence and symptom management in oncology patients

Pediatric Blood &Cancer, EarlyView.


https://ift.tt/2KtkVek

13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer

Genes, Chromosomes and Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2MYvSmi

Novel intra‐genic large deletions of CTNNB1 gene identified in WT desmoid‐type fibromatosis

Genes, Chromosomes and Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KqiNR9

EWS‐FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Koe9Gw

PFN1 Induces drug resistance through Beclin1 Complex mediated autophagy in multiple myeloma

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Km1yjL

Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2K87i4C

Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KqflGb

UNC119 is a binding partner of a tumor suppressor RASSF6 and induces apoptosis and cell cycle arrest via MDM2 and p53

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KkDcdH

Cx43 C terminus Directly Inhibits the Hyper‐phosphorylation of Akt/ERK via Protein‐Protein Interactions in Glioblastoma

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2MtgNrJ

Pharmacodynamic analysis of eribulin safety in breast cancer patients using real‐world post‐marketing surveillance data

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KrLArC

Resistin facilitates metastasis of lung adenocarcinoma via TLR4/Src/EGFR/PI3K/ NF‐κB pathway

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Km1Kje

Lung‐resident natural killer cells control pulmonary tumor growth in mice

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KacAMV

A novel lymphoid enhancer‐binding factor 1‐cytoglobin axis promotes extravasation of osteosarcoma cells into the lungs

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2MqVY0h

FH inactivation in hereditary leiomyomatosis and renal cell cancer is synthetic lethal with ferroptosis induction

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Kb8wwf

The role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KmZAja

Phase II Trial of Biweekly Cetuximab and Irinotecan as Third‐Line Therapy for Pretreated KRAS Exon 2 Wild‐Type Colorectal Cancer

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Kb8qET

Exosomes in cancer development and clinical applications

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KqPEoO

AMPK‐dependent mTOR pathway is involved in flavokawain B‐induced autophagy in thyroid cancer cells

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2K8Dwgh

PIK3CA‐mutation profiling in patients with breast cancer, using a highly sensitive detection system

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KqgoWK

Integrin β1 is an essential factor on vasculogenic mimicry in human cancer cells

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Kb83tZ

Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KnXQ9w

Autophagy inhibition synergizes with calcium mobilization to achieve efficient therapy of malignant gliomas

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Kn4foC

Nab‐paclitaxel interrupt cancer‐stromal interaction through CXCL10 mediated IL‐6 down‐regulation in vitro

Cancer Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2MmIT8b

Randomized study of HPV prevalence and detection of CIN2+ in vaginal self‐sampling compared to cervical specimens collected by medical personnel

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KmTteI

Author's reply to: Implementation and organization of cancer screening in France

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2MszMTr

Eight‐type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV‐positive women

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Kkoh39

Implementation and organization of cancer screening in France

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KrQzVW

Inhaled corticosteroids in COPD and the risk of lung cancer

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2K9OphQ

Coffee and tea consumption and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KeWWzZ

Issue Information

International Journal of Cancer, Volume 143, Issue 3, Page 451-458, 1 August 2018.


https://ift.tt/2KlVZln

Issue Information

International Journal of Cancer, Volume 143, Issue 3, Page 724-725, 1 August 2018.


https://ift.tt/2KdFD2g

Bruno Kyewski 1950‐2018

International Journal of Cancer, Volume 143, Issue 3, Page 459-459, 1 August 2018.


https://ift.tt/2MqoqiZ

The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy‐induced toxicity

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KaNaPq

Somatic late effects in 5‐year survivors of neuroblastoma: A population‐based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2MqooHT

High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Kama2G

Non‐surgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003‐2014: A large international population‐based study

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KphOkj

CIRCULATING TUMOR DNA ANALYSIS ENABLES MOLECULAR CHARACTERIZATION OF PEDIATRIC RENAL TUMORS AT DIAGNOSIS

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Kko1kH

BMI1 enhancer polymorphism underlies chromosome 10p12.31 association with childhood acute lymphoblastic leukemia

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Mqonnj

Pre‐diagnostic plasma concentrations of Fibrinogen, sGPIIb/IIIa, sP‐selectin, sThrombomodulin, Thrombopoietin in relation to cancer risk: Findings from a large prospective study

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KdFBYc

Metastasis directed therapy for liver and lung metastases from colorectal cancer – a population based study

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KlJMx5

Profiles of Brain Metastases: Prioritization of Therapeutic Targets

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KdFzzy

Statin use and mortality among endometrial cancer patients: a Danish nationwide cohort study

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Mtql6r

SOX2‐mediated upregulation of CD24 promotes adaptive resistance towards targeted therapy in melanoma

International Journal of Cancer, Volume 0, Issue ja, -Not available-.


https://ift.tt/2KknYFx

Epidemiology of multiple myeloma in Taiwan, a population based study

Publication date: August 2018
Source:Cancer Epidemiology, Volume 55
Author(s): Chao-Hsiun Tang, Hung-Yi Liu, Hsin-An Hou, Hong Qiu, Kuan-Chih Huang, Sarah Siggins, Lee Anne Rothwell, Yanfang Liu
BackgroundAlthough the incidence of multiple myeloma (MM) in Asia is lower than in Western countries, it is steadily increasing. However, limited data are available that describe the epidemiology of MM in Asia.MethodsWe conducted a retrospective cohort study using the Taiwan National Healthcare Insurance Research database to estimate the disease burden and clinical characteristics of patients with MM in Taiwan. All newly diagnosed confirmed MM patients during 2007–2012 were enrolled. Patients were followed up until death or end of the observation period (December 31, 2013), whichever occurred first.ResultsA total of 2723 newly diagnosed MM patients were included in the cohort analysis, of whom 58.0% (1578/2723) were men. The average age of MM patients was 67.6 years. At the time of diagnosis, the mean Charlson Comorbidity Index was 1.8, 35.3% of patients had anemia, 18.0% had bone fracture, 16.4% had renal disease and 17.3% had pneumonia. The crude annual incidence of newly diagnosed MM increased from 1.74 per 100 000 population in 2007 to 2.27 per 100 000 population in 2012 (p < 0.0001), and the age-adjusted incidence from 1.41 to 1.59 per 100 000 population (p = 0.01). The use of novel treatments expanded over the study period. The crude and age-adjusted annual MM mortality rate did not change significantly over time. Case fatality decreased from 25.5% in 2007 to 19.4% in 2012 (p < 0.0001).ConclusionThe age-adjusted incidence of MM in Taiwan increased by 13% between 2007 and 2012. Despite the introduction of new treatments, MM remains largely incurable with 19.4% mortality.



https://ift.tt/2MZs0S4

Clonal structures of regionally synchronous gastric adenomas and carcinomas

Purpose: Gastric adenoma (GA) is a premalignant lesion that precedes intestinal-type gastric carcinoma (GC). However, genetic progression mechanisms from GA to GC have not been clarified. Experimental design: We performed whole-exome sequencing-based mutational analyses for 15 synchronous pairs of attached GAs and GCs. Results: There was no significant difference in the number of driver mutations or copy number alterations between GAs and GCs. Well-known mutations of TP53, APC, RNF43, and RPL22 were recurrently detected in synchronous GA/GC pairs. In addition, we discovered novel KDM6A, PREX2, FAT1, KMT2C, GLI3 and RPL22 mutations and hypermutation in GAs, but did not identify recurrent drivers for GA-to-GC progression. Clonal structure analyses revealed that most GA/GC pairs exhibit parallel evolution with early divergence rather than stepwise evolution during GA-to-GC progression. Of note, three cases were identified as clonally non-related GA/GC pairs despite the lack of histologic differences. We found differences in dominant mutational signatures 1, 6, 15, and 17 in GA/GC trunks, GA-branches, and GC-branches. Compared to our previous work on synchronous colon adenoma/carcinoma genome structures, where most drivers were in the trunk with parallel evolution, synchronous GA/GC genomes showed a different model of parallel evolution, with many drivers in the branches. Conclusions: The preferred sequence of mutational events during GA-to-GC progression might be more context-dependent than colon adenoma progression. Our results show that non-clonal synchronous GA/GC is common, and that GA genomes have already acquired distinct genomic alterations, suggesting caution in the diagnosis of synchronous GA and GC, especially in residual or recurrent cases.



https://ift.tt/2KoCada

The light chain IgLV3-21 defines a new poor prognostic subgroup in Chronic Lymphocytic Leukemia: results of a multicenter study

Purpose: Unmutated (UM) immunoglobulin heavy chain variable region (IgHV) status or IgHV3-21 gene usage is associated with poor prognosis in chronic lymphocytic leukemia (CLL) patients. Interestingly, IgHV3-21 is often co-expressed with light chain IgLV3-21, which is potentially able to trigger cell-autonomous BCR-mediated signaling. However, this light chain has never been characterized independently of the heavy chain IgHV3-21. Experimental Design: We performed total RNA sequencing in 32 patients and investigated IgLV3-21 prognostic impact in terms of treatment-free (TFS) and overall (OS) survival in 3 other independent cohorts for a total of 813 patients. IgLV3-21 presence was tested by real-time PCR and confirmed by Sanger sequencing. Results: Using total RNA sequencing to characterize 32 patients with high-risk CLL, we found a high frequency (28%) of IgLV3-21 rearrangements. Gene set enrichment analysis revealed that these patients express higher levels of genes responsible for ribosome biogenesis and translation initiation (P<0.0001) as well as MYC target genes (P=0.0003). Patients with IgLV3-21 rearrangements displayed a significantly shorter TFS and OS (P<0.05), particularly in IgHV-mutated patients. In each of the 3 independent validation cohorts, we showed that IgLV3-21 rearrangements -similar to UM IgHV status- conferred poor prognosis compared to mutated IgHV (P<0.0001). Importantly, we confirmed by multivariate analysis that this was independent of IgHV mutational status or subset #2 stereotyped receptor (P<0.0001). Conclusions: We have demonstrated for the first time that a light chain can impact CLL prognosis and that IgLV3-21 light chain usage defines a new subgroup of CLL patients with poor prognosis.



https://ift.tt/2N0YafT

Characterization of alternative splicing events in HPV negative head and neck squamous cell carcinoma identifies an oncogenic DOCK5 variant

Purpose: Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers worldwide and alternative splicing is considered to play important roles in tumor progression. Our study is designed to identify alternative splicing events (ASEs) in HPV negative HNSCC. Experimental Design: RNA sequencing data of 407 HPV negative HNSCC and 38 normal samples were obtained from The Cancer Genome Atlas (TCGA) and splice junctions were discovered using MapSplice. Outlier analysis was used to identify significant splicing junctions between HPV negative HNSCC and normal samples. To explore the functional role of the identified DOCK5 variant, we checked its expression with qRT-PCR in a separate primary tumor validation set and performed proliferation, migration and invasion assays. Results: 580 significant splicing events were identified in HPV negative HNSCC and the most common type of splicing events was an alternative start site (33.3%). The prevalence of a given individual ASE among the tumor cohort ranged from 9.8% and 64.4%. Within the 407 HPV negative HNSCC samples in TCGA, the number of significant ASEs differentially expressed in each tumor ranged from 17 to 290. We identified a novel candidate oncogenic DOCK5 variant confirmed using qRT-PCR in a separate primary tumor validation set. Loss- and gain-of-function experiments indicated that DOCK5 variant promoted proliferation, migration and invasion of HPV negative HNSCC cells, and patients with higher expression of DOCK5 variant showed decreased overall survival. Conclusion: Analysis of ASEs in HPV negative HNSCC identifies multiple alterations likely related to carcinogenesis, including an oncogenic DOCK5 variant.



https://ift.tt/2KnpyTK

Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer

Purpose: Despite the challenge to directly target mutant KRAS due to its high GTP affinity, some agents are under development against downstream signaling pathways, such as MEK inhibitors. However, it remains controversial whether MEK inhibitors can boost current chemotherapy in KRAS-mutant lung tumors in clinic. Considering the genomic heterogeneity among lung cancer patients, it is valuable to test potential therapeutics in KRAS-mutation driven mouse models. Experimental Design: We first compared the pERK1/2 level in lung cancer samples with different KRAS substitutions and generated a new genetically engineered mouse model whose tumor was driven by KRAS G12C, the most common KRAS mutation in lung cancer. Next, we evaluated the efficacy of selumetinib or its combination with chemotherapy, in KRAS G12C tumors compared to KRAS G12D tumors. Moreover, we generated KRAS G12C/p53 R270H model to explore the role of a dominant negative p53 mutation detected in patients in responsiveness to MEK inhibition. Results: We determined higher pERK1/2 in KRAS G12C lung tumors compared to KRAS G12D. Using mouse models, we further identified that KRAS G12C tumors are significantly more sensitive to selumetinib compared with Kras G12D tumors. MEK inhibition significantly increased chemotherapeutic efficacy and progression-free survival of KRAS G12C mice. Interestingly, p53 co-mutation rendered KRAS G12C lung tumors less sensitive to combination treatment with selumetinib and chemotherapy. Conclusions: Our data demonstrate that unique KRAS mutations and concurrent mutations in tumor-suppressor genes are important factors for lung tumor responses to MEK inhibitor. Our preclinical study supports further clinical evaluation of combined MEK inhibition and chemotherapy for lung cancer patients harboring KRAS G12C and wildtype p53 status.



https://ift.tt/2MZFL3f

Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients

Purpose: Toca 511 is a gammaretroviral replicating vector encoding cytosine deaminase that selectively infects tumor cells and coverts the antifungal drug 5-fluorocytosine into the antineoplastic drug 5-fluorouracil, which directly kills tumor cells and stimulates anti-tumor immune responses. As part of clinical monitoring of Phase 1 clinical trials in recurrent high grade glioma we have performed extensive molecular analyses of patient specimens in order to track vector fate. Experimental Design: Toca 511 and Toca FC (extended-release 5-fluorocytosine) have been administered to 127 high grade glioma patients across three phase I studies. We measured Toca 511 RNA and DNA levels in available body fluids and tumor samples from patients to assess tumor specificity. We mapped Toca 511 integration sites and sequenced integrated Toca 511 genomes from patient samples with detectable virus. We measured Toca 511 levels in a diverse set of tissue samples from one patient. Results: Integrated Toca 511 is commonly detected in tumor samples and is only transiently detected in blood in a small fraction of patients. There was no believable evidence for clonal expansion of cells with integrated Toca 511 DNA, or preferential retrieval of integration sites near oncogenes. Toca 511 sequence profiles suggest most mutations are caused by APOBEC cytidine deaminases acting during reverse transcription. Tissue samples from a single whole-body autopsy affirm Toca 511 tumor selectivity. Conclusions: Toca 511 and Toca FC treatment was not associated with inappropriate integration sites and clonal expansion. The vector is tumor selective and persistent in patients who received Toca 511 injections.



https://ift.tt/2KojHxB

The Integration of Radiotherapy With Immunotherapy for the Treatment of Non-Small Cell Lung Cancer

Five-year survival rates for non-small cell lung cancer (NSCLC) range from 14% to 49% for stage I to stage IIIA disease, and are <5% for stage IIIB/IV disease. Improvements have been made in the outcomes of patients with NSCLC due to advancements in radiotherapy (RT) techniques, the use of concurrent chemotherapy with radiation, and the emergence of immunotherapy as first- and second-line treatment in the metastatic setting. RT remains the mainstay treatment in patients with inoperable early-stage NSCLC, and is given concurrently or sequentially with chemotherapy in patients with locally advanced unresectable disease. There is emerging evidence that RT not only provides local tumor control, but may also influence systemic control. Multiple preclinical studies have demonstrated that RT induces immunomodulatory effects in the local tumor microenvironment, supporting a synergistic combination approach with immunotherapy to improve systemic control. Immunotherapy options that could be combined with RT include programmed cell death-1/programmed cell death ligand-1 blockers, as well as investigational agents such as OX-40 agonists, toll-like receptor agonists, indoleamine 2,3-dioxygenase-1 inhibitors, and cytokines. Here, we describe the rationale for the integration of RT and immunotherapy in patients with NSCLC, present safety and efficacy data that support this combination strategy, review planned and ongoing studies, and highlight unanswered questions and future research needs.



https://ift.tt/2tu41lI

Talazoparib is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts

Purpose: Small cell lung cancer (SCLC) is an aggressive malignancy with a critical need for novel therapies. Our goal was to determine whether PARP inhibition could sensitize SCLC cells to ionizing radiation (IR) and if so, to determine the contribution of PARP trapping to radiosensitization. Methods and Materials: Short-term viability assays and clonogenic survival assays (CSA) were used to assess radiosensitization in six SCLC cell lines. Doses of veliparib and talazoparib with equivalent enzymatic inhibitory activity but differing PARP trapping activity were identified and compared in CSAs. Talazoparib, IR, and their combination were tested in three patient-derived xenograft (PDX) models. Results: Talazoparib radiosensitized 5 of 6 SCLC cell lines in short-term viability assays and confirmed in 3 of 3 cell lines by CSAs. Concentrations of 200 nM talazoparib and 1600 nM veliparib similarly inhibited PAR polymerization; however, talazoparib exhibited greater PARP trapping activity that was associated with superior radiosensitization. This observation further correlated with an increased number of double-stranded DNA breaks induced by talazoparib as compared to veliparib. Finally, a dose of 0.2 mg/kg talazoparib in vivo caused tumor growth inhibition in combination with IR but not as a single agent in 3 SCLC PDX models. Conclusions: PARP inhibition effectively sensitizes SCLC cell lines and PDXs to IR, and PARP trapping activity enhances this effect. PARP inhibitors, especially those with high PARP trapping activity, may provide a powerful tool to improve the efficacy of radiation therapy in SCLC.



https://ift.tt/2MpcFJu

Endoglin expression on cancer-associated fibroblasts regulates invasion and stimulates colorectal cancer metastasis

Purpose: Cancer-associated fibroblasts (CAFs) are a major component of the colorectal cancer (CRC) tumor microenvironment. CAFs play an important role in tumor progression and metastasis, partly through the transforming growth factor-β (TGF-β) signaling pathway. We investigated whether the TGF-β family co-receptor endoglin is involved in CAF-mediated invasion and metastasis. Experimental design: CAF-specific endoglin expression was studied in CRC resection specimens using immunohistochemistry and related to metastases-free survival. Endoglin-mediated invasion was assessed in vitro by transwell invasion, using primary CRC-derived CAFs. Effects of CAF-specific endoglin expression on tumor cell invasion were investigated in a CRC zebrafish model, while liver metastases were assessed in a mouse model. Results: CAFs specifically at invasive borders of CRC express endoglin and increased expression intensity correlated with increased disease stage. Endoglin-expressing CAFs were also detected in lymph node and liver metastases, suggesting a role in CRC metastasis formation. In stage-II CRC, CAF-specific endoglin expression at invasive borders correlated with poor metastasis-free survival. In vitro experiments revealed that endoglin is indispensable for bone morphogenetic protein (BMP)-9-induced signaling and CAF survival. Targeting endoglin using the neutralizing antibody TRC105 inhibited CAF invasion in vitro. In zebrafish, endoglin-expressing fibroblasts enhanced colorectal tumor cell infiltration into the liver and decreased survival. Finally, CAF-specific endoglin targeting with TRC105 decreased metastatic spread of CRC cells to the mouse liver. Conclusions: Endoglin-expressing CAFs contribute to CRC progression and metastasis. TRC105 Treatment inhibits CAF invasion and tumor metastasis, indicating an additional target beyond the angiogenic endothelium, possibly contributing to beneficial effects reported during clinical evaluations.



https://ift.tt/2MXxSLA

Outcomes of patients with a pretransplant history of early-stage melanoma

A history of melanoma within the preceding 5 years is commonly considered a contraindication to solid organ transplantation. We investigated how a pretransplant history of melanoma impacts patient survival and melanoma recurrence. Institutional Review Board approval was obtained, and Duke's retrospective database was used to identify 4552 patients who underwent a solid organ transplant at Duke University from 1 January 2001 to 31 December 2016. Data with regard to the transplant, melanoma characteristics, rejection episodes, and survival were recorded. Of 4552 patients who underwent a solid organ transplant, 12 (0.3%) had a history of melanoma before transplant (six with melanoma in situ and six with stage I disease). The median time between melanoma diagnosis and transplant was 4.13 years (range: 1.1–13.3 years). The study cohort consisted of four liver transplants, four lung transplants, one kidney transplant, one heart transplant, one small bowel transplant, and one multivisceral transplant. At the median follow-up time of 2.8 years, 10 (83.3%) patients were alive. In nonmelanoma cohorts, the 3-year survival is 70% for thoracic transplants, 78% for liver transplants, and 88% for kidney transplants. In well-selected patients with a history of early-stage melanoma and an appropriate time interval between melanoma treatment and transplant, post-transplant outcomes are favorable. Presented in part at the 41st Annual Southeastern Consortium for Dermatology and 2018 Meeting of the American Academy of Dermatology. Correspondence to Paul J. Mosca, MD, PhD, MBA, Department of Surgery, Duke Cancer Institute, Duke University Health System, DUMC 3966, 10 Bryan Searle Drive, 466G Seeley G Mudd, Durham, NC 27707, USA Tel: +1 919 684 4064; fax: +1 919 684 6044; e-mail: paul.mosca@duke.edu Received March 13, 2018 Accepted May 9, 2018 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2ItpWOK

Bench-to-clinic development of imageable drug-eluting embolization beads: finding the balance

Future Oncology, Ahead of Print.


https://ift.tt/2ItQUpq

Perioperative Blood Management, Red Cell Recovery (Cell Salvage) Practice in an Australian Tertiary Hospital: A Hospital District Clinical Audit

BACKGROUND: Data on red cell recovery (cell salvage) utilization in Australia are limited and national guidance is based on a single Australian audit conducted at a hospital that excludes cardiothoracic surgery. This clinical audit aimed to analyze the utility of red cell recovery at a tertiary health care facility which includes cardiothoracic surgery. Secondary aims of this study were to identify specific surgical procedures in which red cell recovery is most beneficial and to quantify this benefit. METHODS: Data were collected retrospectively on all adult red cell recovery surgical cases conducted at a 2-campus health care facility over a 2-year period. Case demographic data, including surgical procedure, red blood cell return, and hematocrit levels, were collated and analyzed against national cell salvage guidelines. Average return per procedure was collated into a red cell recovery benefit analysis. RESULTS: A total of 471 red cell recovery cases for 85 surgical procedures met inclusion criteria. Of the 7 surgical subspecialties utilizing red cell recovery, orthopedics utilized the most cases (22.9%, n = 108), followed by urology (19.1%, n = 90) and cardiothoracic surgery (18.3%, n = 86). Radical retropubic prostatectomy (11.7%), revision (7.6%), and primary (6.6%) total hip replacement were the most utilized procedures. Red cell recovery use had a 79% compliance rate with national guidelines. Vascular surgery and urology had the highest average return at 699 mL (interquartile range, 351–1127; CI, 449–852) and 654 mL (interquartile range, 363–860; CI, 465–773), respectively. CONCLUSIONS: Overall, our center demonstrated good compliance with national red cell recovery guidelines. This audit adds to the existing data on red cell recovery practice in Australia and provides a benefit-specific surgical procedure guideline that includes cardiothoracic surgery. Accepted for publication May 5, 2018. Funding: None. The authors declare no conflicts of interest. Gold Coast Health Human Research Ethics Committee number: HREC/17/QGC/130. Reprints will not be available from the authors. Address correspondence to Elizabeth A. Forrest, MD, Department of Anaesthetics, Gold Coast Hospital and Health Service, 1 Hospital Blvd, Southport, QLD 4214, Australia. Address e-mail to elizabeth.forrest3@health.qld.gov.au. © 2018 International Anesthesia Research Society

https://ift.tt/2N0GZLr

Treating Anemia in the Preanesthesia Assessment Clinic: Results of a Retrospective Evaluation

BACKGROUND: Perioperative anemia is challenging during hospital stay because anemia and red blood cell (RBC) transfusions are associated with an increased morbidity and mortality. With the implementation of patient blood management (PBM), a preanesthesia assessment clinic to screen and treat anemia before elective surgery was institutionalized at Muenster University Hospital, Germany. The main objective of this study was to evaluate the association between treating preoperative anemic patients with intravenous iron (IVI) and (primarily) presurgical hemoglobin levels and (secondarily) use of RBCs and mortality. METHODS: Between April 1, 2014, and July 4, 2016, patients scheduled for elective surgery with a risk for RBC transfusions >10% in 2013 were screened for preoperative anemia and, if indicated, treated with IVI. Patients' data, time span between visit in the anesthesia/PBM clinic and surgery, demographic data, type of surgery, the difference of hemoglobin levels between visit and surgery, RBC transfusion, infectious-related International Classification of Disease codes during hospital stay, and 1-year survival were determined retrospectively by screening electronic data files. In addition, patients were interviewed about adverse events, health-related events, and infections via telephone 30, 90, and 365 days after visiting the anesthesia/PBM clinic. RESULTS: A total of 1101 patients were seen in the anesthesia/PBM clinic between days −28 and −1 (median [Q1–Q3], −3 days [−1, −9 days]) before elective surgery. Approximately 29% of patients presented with anemia, 46.8% of these anemic patients were treated with ferric carboxymaltose (500–1000 mg). In the primary analysis, hemoglobin levels at median were associated with a reduction between the visit in the anesthesia/PBM clinic and the surgery in all nonanemic patients on beginning of medical treatment (nonanemic patients at median −2.8 g/dL [−4, −0.9 g/dL], while anemic patients without IVI presented with median differences of −0.8 g/dL [−2, 0 g/dL] and anemic patients with IVI of 0 g/dL [−1.0, 0.5 g/dL]). Hemoglobin levels raised best at substitution 22–28 days before surgery (0.95 g/dL [−0.35, 1.18 g/dL]). Due to the selection criteria, transfusion rates were high in the cohort. Overall, there was no association between IVI treatment and the use of RBC transfusions (odds ratio for use of RBCs in anemic patients, no IVI versus IVI: 1.14; 95% confidence interval, 0.72–1.82). Patients treated with or without IVI presented a comparable range of International Classification of Disease codes related to infections. Telephone interviews indicated similar adverse events, health-related events, and infections. Cox regression analysis showed an association between anemia and reduced survival, regardless of IVI. CONCLUSIONS: An anemia clinic within the preanesthesia assessment clinic is a feasible and effective approach to treat preoperative anemia. The IVI supplementation was safe but was associated with decreased RBC transfusions in gynecology/obstetric patients only. The conclusions from this retrospective analysis have to be tested in prospective, controlled trials. Accepted for publication May 8, 2018. Funding: This work was supported by an industrial grant for the implementation of patient blood management to H.V.A. (AF 700501). A.U.S. receives funding from the German Research Foundation (DFG-STE1895-4/1). The authors declare no conflicts of interest. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (https://ift.tt/KegmMq). Clinical trial number: The implementation of Patient Blood Management and treatment of anemia was registered at clinicaltrial.gov NCT01820949. I. Ellermann and A. Bueckmann contributed equally and share first authorship. Reprints will not be available from the authors. Address correspondence to Andrea U. Steinbicker, MD, PD, MPH, Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Muenster, Albert-Schweitzer Campus 1, Bldg A1, Muenster 48149, Germany. Address e-mail to andrea.steinbicker@ukmuenster.de. © 2018 International Anesthesia Research Society

https://ift.tt/2Mrm17o

Usefulness of the Korean Version of the CAGE-Adapted to Include Drugs Combined With Clinical Predictors to Screen for Opioid-Related Aberrant Behavior

BACKGROUND: As national opioid consumption in South Korea has soared, well-validated screening tools for opioid use disorder (OUD) have become indispensable. The aims of our study were to evaluate OUD using the Korean version of the CAGE-Adapted to Include Drugs (CAGE-AID) and the CAGE-Opioid (an alternative version of the CAGE-AID), and to investigate clinical predictors that might be useful to screen for OUD in conjunction with the CAGE-AID/Opioid questionnaires. METHODS: A single-center, prospective, observational study was performed. After linguistic validation of the Korean version of the CAGE-AID/Opioid questionnaires, we assessed OUD in patients with chronic opioid treatment. Multivariable logistic models of the CAGE-AID/Opioid questionnaires combined with relevant clinical predictors were established. Then, the receiver operating characteristic curve analysis of the multivariable CAGE-AID/Opioid models was conducted to assess diagnostic accuracy to screen for OUD. Next, we calculated predicted probability with >85% sensitivity and >50% specificity in each CAGE-AID and CAGE-Opioid model. Using the optimal value of the predicted probability, a cutoff score of the CAGE-AID/Opioid questionnaires combined with the relevant clinical factors was suggested to screen for OUD. RESULTS: Among 201 participants, 51 patients showed ≥1 OUDs. In the multivariable regression model, male sex, comorbid neuropsychiatric disorder, and current heavy drinking significantly remained as clinical variables to predict OUD combined with the scores of the Korean CAGE-AID/Opioid questionnaire. The area under the curve was 0.77 (95% confidence interval, 0.71–0.83) for the CAGE-AID model and 0.78 (95% confidence interval, 0.71–0.83) for the CAGE-Opioid model. The optimal predicted probability values to screen for OUD in the CAGE-AID/Opioid models were >0.135 (sensitivity, 0.86; specificity, 0.52) and >0.142 (sensitivity, 0.86; specificity, 0.53), respectively. When we used these predictive probabilities, the cutoff score of the CAGE-AID/Opioid questionnaires ranged from 0 to 3, which was dependent on the presence of the relevant clinical variables in each model. CONCLUSIONS: In this study, one fourth of the total participants with chronic opioid treatment showed OUD in the Korean population. The multivariable models of the CAGE-AID/Opioid with sex, comorbid neuropsychiatric disorder, and current heavy drinking are valid parameters to screen for OUD, with the cutoff scores of the CAGE-AID/Opioid questionnaires ranging from 0 to 3 depending on the presence of the clinical variables. Accepted for publication May 8, 2018. Funding: None. The authors declare no conflicts of interest. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (https://ift.tt/KegmMq). Reprints will not be available from the authors. Address correspondence to Jee Youn Moon, MD, PhD, FIPP, CIPS, Department of Anesthesiology and Pain Medicine, Seoul National University Hospital College of Medicine, 110 Daehang-ro, Jongno-gu, Seoul 110–744, Korea. Address e-mail to jymoon0901@gmail.com. © 2018 International Anesthesia Research Society

https://ift.tt/2N2tfjh

Pediatric Intensive Care, 1st ed

No abstract available

https://ift.tt/2MrlrXg

Incidence and Epidemiology of Perioperative Transfusion-Related Pulmonary Complications in Pediatric Noncardiac Surgical Patients: A Single-Center, 5-Year Experience

BACKGROUND: Transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO) are the leading causes of transfusion-related fatalities. While these transfusion-related pulmonary complications (TRPCs) have been well detailed in adults, their burden in pediatric subsets remains poorly defined. We sought to delineate the incidence and epidemiology of pediatric TRPCs after intraoperative blood product transfusion. METHODS: In this retrospective cohort study, we evaluated all consecutive pediatric patients receiving intraoperative blood product transfusions during noncardiac surgeries between January 2010 and December 2014. Exclusion criteria were cyanotic heart disease, preoperative respiratory insufficiency, extracorporeal membrane oxygenation, and American Society of Anesthesiologists physical status VI. Medical records were electronically screened to identify those with evidence of hypoxemia, and in whom a chest x-ray was obtained within 24 hours of surgery. Records were then manually reviewed by 2 physicians to determine whether they met diagnostic criteria for TACO or TRALI. Disagreements were adjudicated by a third senior physician. RESULTS: Of 19,288 unique pediatric surgical patients, 411 were eligible for inclusion. The incidence of TRPCs was 3.6% (95% confidence interval [CI], 2.2–5.9). TACO occurred in 3.4% (95% CI, 2.0–5.6) of patients, TRALI was identified in 1.2% (95% CI, 0.5–2.8), and 1.0% (95% CI, 0.4–2.5) had evidence for both TRALI and TACO. Incidence was not different between males (3.4%) and females (3.8%; P = .815). Although a trend toward an increased incidence of TRPCs was observed in younger patients, this did not reach statistical significance (P = .109). Incidence was comparable across subsets of transfusion volume (P = .184) and surgical specialties (P = .088). Among the 15 patients experiencing TRPCs, red blood cells were administered to 13 subjects, plasma to 3, platelets to 3, cryoprecipitate to 2, and autologous blood to 3. Three patients with TRCPs were transfused mixed blood components. CONCLUSIONS: TRPCs occurred in 3.6% of transfused pediatric surgical patients, with the majority of cases attributable to TACO, congruent with adult literature. The frequency of TRPCs was comparable between genders and across surgical procedures and transfusion volumes. The observed trend toward increased TRPCs in younger children warrants further consideration in future investigations. Red blood cell administration was the associated component for the majority of TRPCs, although platelets demonstrated the highest risk per component transfused. Mitigation of perioperative risk associated with TRPCs in pediatric patients is reliant on further multiinstitutional studies powered to examine patterns and predictors of this highly morbid entity. Accepted for publication May 8, 2018. Funding: D.J.K. receives funding via National Institutes of Health grant R01-HL121232. The authors declare no conflicts of interest. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (https://ift.tt/KegmMq). Reprints will not be available from the authors. Address correspondence to Leanne Thalji, BM, MSc, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905. Address e-mail to thalji.leanne@mayo.edu. © 2018 International Anesthesia Research Society

https://ift.tt/2ttBoW8

US Food and Drug Administration Disruption of Generic Drug Market Increases Hospital Costs

BACKGROUND: The purpose of the US Food and Drug Administration's Marketed Unapproved Drugs Initiative is to decrease marketing of older unapproved medications. The administration has recently extended its rulings by including sterile injectable drugs administered in the inpatient environment. The impact of this initiative on the inpatient environment has been minimally studied. METHODS: Consecutive retrospective purchase data of vasopressin for injection (vasopressin) and neostigmine methylsulfate for injection (neostigmine) from 720 hospitals and 746 hospitals, respectively, were included. Purchases occurred from January 1, 2010 to December 31, 2016. The average noncontract drug price was calculated and compared to the purchase data during the impact of the initiative. Comparison was made of hospital purchases made before and after the initiative. The year 2014 was considered a washout transition year due to the large amounts of discontinued unapproved formulations that were still available and purchased by hospitals. The analysis was completed using a matched paired t test. RESULTS: The noncontract price for vasopressin increased from $12.83 per vial to $158.83 per vial (1138% increase) and for neostigmine from $27.74 per vial to $175.14 per vial (531% increase) across the pre- and postinitiative intervals; however, purchase volumes after the price increases were not found to have a statistically significant difference compared to purchases before the price increases (P = .98 and P = .4, respectively). CONCLUSIONS: Health systems have experienced a significant cost increase of vasopressin and neostigmine and are absorbing price increases for these older, generic sterile injectable drugs. Accepted for publication May 21, 2018. Funding: None. The authors declare no conflicts of interest. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (https://ift.tt/KegmMq). Reprints will not be available from the authors. Address correspondence to Philip J. Almeter, PharmD, Department of Pharmacy Services, University of Kentucky HealthCare, 800 Rose St, H110, Lexington, KY 40536. Address e-mail to philip.almeter@uky.edu. © 2018 International Anesthesia Research Society

https://ift.tt/2KkSz2d

Society of Anesthesia and Sleep Medicine Guideline on Intraoperative Management of Adult Patients With Obstructive Sleep Apnea

The purpose of the Society of Anesthesia and Sleep Medicine Guideline on Intraoperative Management of Adult Patients With Obstructive Sleep Apnea (OSA) is to present recommendations based on current scientific evidence. This guideline seeks to address questions regarding the intraoperative care of patients with OSA, including airway management, anesthetic drug and agent effects, and choice of anesthesia type. Given the paucity of high-quality studies with regard to study design and execution in this perioperative field, recommendations were to a large part developed by subject-matter experts through consensus processes, taking into account the current scientific knowledge base and quality of evidence. This guideline may not be suitable for all clinical settings and patients and is not intended to define standards of care or absolute requirements for patient care; thus, assessment of appropriateness should be made on an individualized basis. Adherence to this guideline cannot guarantee successful outcomes, but recommendations should rather aid health care professionals and institutions to formulate plans and develop protocols for the improvement of the perioperative care of patients with OSA, considering patient-related factors, interventions, and resource availability. Given the groundwork of a comprehensive systematic literature review, these recommendations reflect the current state of knowledge and its interpretation by a group of experts at the time of publication. While periodic reevaluations of literature are needed, novel scientific evidence between updates should be taken into account. Deviations in practice from the guideline may be justifiable and should not be interpreted as a basis for claims of negligence. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. Accepted for publication March 27, 2018. Funding: None. Conflicts of Interest: See Disclosures at the end of the article. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (https://ift.tt/KegmMq). LMA Unique is a registered trademark of Teleflex Incorporated or its affiliates. Reprints will not be available from the authors. Address correspondence to Stavros G. Memtsoudis, MD, PhD, Departments of Anesthesiology, Critical Care & Pain Management and Public Health, Weill Cornell Medical College and Hospital for Special Surgery, 535 E 70th St, New York, NY 10021. Address e-mail to memtsoudiss@hss.edu. © 2018 International Anesthesia Research Society

https://ift.tt/2N1MSYY

Use of Earlier-Reported Rotational Thromboelastometry Parameters to Evaluate Clotting Status, Fibrinogen, and Platelet Activities in Postpartum Hemorrhage Compared to Surgery and Intensive Care Patients

BACKGROUND: Rotational thromboelastometry (ROTEM) can provide clinical information in 10–20 minutes for guiding administration of fibrinogen, platelets, and fresh frozen plasma products. While ROTEM testing is well established for cardiac and other surgeries, it is less characterized for use in postpartum hemorrhage (PPH) patients. We wanted to determine if the earlier-measured ROTEM parameters (α-angle and amplitude at 10 minutes [A10]) could replace the later parameters (amplitude at 20 minutes and maximum amplitude [maximum clot firmness {MCF}]) in all patient groups studied. We also correlated the A10 and α-angle of the EXTEM and FIBTEM tests to the fibrinogen levels and platelet counts in these patients. METHODS: We retrospectively analyzed 100 sets of EXTEM and FIBTEM results ordered on patients undergoing operations for PPH, patients in intensive care units (ICU), and those undergoing cardiothoracic surgery (cardiothoracic operating room [C/T OR]). We determined if the correlations among the various parameters were similar among the PPH, ICU, and C/T OR patients. RESULTS: As expected, the EXTEM A10 (A10EX) and FIBTEM A10 (A10FIB) correlated highly to the EXTEM MCF and FIBTEM MCF in all patient groups. The A10EX parameter correlated significantly to both fibrinogen and platelet levels, and the A10FIB correlated to the fibrinogen levels. The difference between the A10EX and the A10FIB (PLTEM) is related to platelet activity, and we found that the PLTEM and platelet count correlated highly for all 100 PPH patients (r = 0.80), C/T OR patients (r = 0.70), and ICU patients (r = 0.66), despite 4 high platelet counts with relatively low PLTEM values in the ICU group. The earlier-reported parameter EXTEM α angle (α-EX) is an excellent indicator of the A10EX, with an α-EX ≥65° (ie, normal) giving a >96% probability that the A10EX was ≥44 mm, and an α-EX value below 65 mm giving an 86% probability that the A10EX was

https://ift.tt/2MpwVuF